T HE established value of steroid administration in reducing cerebral edema associated with brain tumors 9 has led to the investigation of steroid therapy for other neurosurgical conditions, including acute brain trauma. Animal experiments have provided variable results. Some studies, using cold injury, demonstrated benefit if therapy preceded trauma, 17,20,21 while Kobrine and Kempe 15 showed prolonged survival and reduction of cerebral edema using high-dose steroids 1 hour after acceleration/deceleration injury in the monkey. However, steroid therapy given after cold injury consistently failed to show benefit in several animal models. 3'4'6'19 Similarly, Tornheim and McLaurin 26 reported no improvement with dexamethasone therapy following acute cranial impact from a Remington humane stunner in cats.
Earlier clinical investigations proved equally inconclusive. Some studies claimed that steroid administration, particularly in high doses (> 100 mg in the first 24 hours), improved mortality and morbidity rates following severe head injury. 7'8'~~ However, other trials have failed to show any such benefit, l'1z'~3 Most of these studies comprised small numbers of patients without a control group, and therefore several doubleblind prospective controlled trials were instituted during the late 1970's to clarify this controversy. Three such studies have been published to date and no advantage from high-dose steroid therapy in the management of severe head injury has emerged. 2'5'z4 In addition, Gudeman and colleagues l~ found that steroid administration did not influence intracranial pressure (ICP) after head injury, but they reported a 50% incidence of gastroin-testinal (GI) ulceration and 85% incidence of hyperglycemia in 20 patients treated with high-dose methylprednisolone (2 gm/day). However, in the study by Marshall and coworkers, ~6 121 neurosurgical patients treated with high-dose steroids had no increase in complication rate, and Braakman and colleagues 2 reported no significant increase in GI bleeding or respiratory complications with high-dose steroid therapy.
The present study is the first prospective doubleblind controlled trial of high-dose dexamethasone to combine information on the ICP effects with outcome. It adds further evidence on the problems of the side effects with this treatment regimen.
Clinical Material and Methods
The study group included 130 severely head-injured patients who were randomly allocated to receive dexamethasone or placebo. Patients receiving incorrect administration of steroid or placebo infusions during the trial period, and those receiving steroids prior to admission to the neurosurgical centers were excluded. Two patients, both in the dexamethasone group, were considered brain-dead on admission to the intensive care unit (ICU), based on the criteria of: 1) apnea on admission, necessitating intubation and ventilation; 2) absence of pupillary reaction or eye movements on admission; 3) absence of electrical activity on the cerebral function monitor; and 4) mean ICP equal to mean blood pressure on admission to the ICU. These patients are denoted dead on arrival in the results.
Management comprised immediate resuscitation, emergency skull and cervical spine x-ray films, serial Glasgow Coma Scale (GCS) assessments, computerized tomography scanning within 2 hours of admission to the neurosurgical center, and surgical intervention where appropriate. Patients received an intravenous bolus dose of either dexamethasone (50 mg for adults, 0.75 mg/kg for children) or placebo shortly after admission to the neurosurgical center; 40 of the 68 patients in the steroid group received the bolus within 6 hours of injury and 50 within 8 hours of injury. All 62 patients in the placebo group received the bolus within 6 hours of admission to the neurosurgical center. Following admission to the ICU, patients received crystalloid infusions with or without added dexamethasone from identical packs. Adults received 100 rag/day of dexamethasone on Days 1, 2, and 3, 50 mg on Day 4, and 25 mg on Day 5 by continuous intravenous infusion. Children received proportionate intravenous doses calculated on a weight basis.
All patients underwent controlled hypocapnic ventilation after admission to the ICU, with management according to a standardized protocol including prophylactic antacid therapy for prevention of stress ulceration. Continuous ICP monitoring was instituted in all patients using a Leeds screw device or catheter placed in the surface subarachnoid space. If ICP exceeded 20 mm Hg, it was reduced with osmotic diuretic agents (mannitol) and/or a hypnotic infusion of barbiturates (Althesin, 3 mg/ml; or Alphaxalone, 9 mg/ml) or etomidate.
The steroid-and placebo-treated groups did not differ significantly in age distribution or admission GCS scores. In this study, all comparisons involving the GCS were based on the preintubation score in order to include any benefits of early resuscitation and to incorporate patients who deteriorated after admission despite resuscitation because of the severity of their injury.
Comparison of the time of injury to determination of the GCS score revealed that more patients were assessed in the first 2 hours after head injury in the steroidtreated group, but that the groups were evenly balanced by 4 hours after injury. The time from injury to admission to the ICU was also similar in the two groups.
Comparison of the intracranial pathology, classified according to the presence or absence of a surgically treatable intracranial hematoma, demonstrated no difference between the steroid-and placebo-treated groups, and there was no difference in the incidence of skull fractures or associated injuries. When patients admitted with GCS scores of 8 or more were excluded, the two groups remained similar in the above respects. A summary of the patients is given in Table 1 . * In no parameter was there a significant difference between groups. GCS = Glasgow Coma Scale; DOA = dead on arrival at the hospital; ICU = intensive care unit.
Results

Outcome
Outcome was assessed 6 months after injury using the Glasgow Outcome Scale classification of dead, vegetative, severely disabled, moderately disabled, and good recovery. ~4 Outcome appeared worse in the steroid-treated group, with 33 (49%) patients dead or vegetative compared to 22 (35.5%) in the placebo group, although this difference did not reach statistical significance (Table 2 ). These observations still apply after exclusion of patients admitted with a preintubation GCS score of 8 or more. When considering patients who survived to 6 months, steroid therapy failed to influence the number of survivors in any subgroup of severity of injury, as assessed by the preintubation GCS scores.
When the 6-month outcome is compared with intracranial pathology, mortality appears higher in the steroid-treated group with surgical lesions, although the difference is not statistically significant, whether or not patients with preintubation GCS scores of 8 or more are included (Table 3) . This difference does not appear to be attributable to the incidence of severe associated Table 2 ); DOA = dead on arrival at the hospital. injuries in the two pathological categories. If 6-month outcome is compared between steroid and placebo groups in patients with major chest or trunk trauma, no difference emerges.
Cause of Death
The cause of death was classified by allocating a total of 5 points per patient between four categories: primary brain death, expanding intracranial lesion, other intracranial complications, and extracranial complications. The placebo group scores can be adjusted to allow for the fact that 33 patients died in the steroid group compared to 21 in the placebo group (multiply the placebo score in each of the four categories by 33/21). If this adjustment is made, a significant difference in distribution of the cause of death emerges, using chisquare analysis between the two groups (0.01 > p > 0.001), due to a predominance of primary brain death in the steroid group and of extracranial complications in the placebo group (Table 4) . No significant difference was demonstrated between the time from injury to death in the two groups.
Intracranial Pressure
Peak sustained mean ICP, not attributable to noxious stimulation, was higher in both groups during the 24 to 48 hours following entry to the ICU than the mean ICP at the time of admission to the ICU (Table 5) . When the ICP trend between steroid-and placebo-treated groups were compared, no statistically significant dif- ference emerged, whether or not patients with preintubation GCS scores of 8 or more were included.
Comparison of the peak sustained unstimulated mean ICP during the first 48 hours following admission to the ICU between the two groups failed to demonstrate any difference (Table 6 ). No difference in the incidence or severity of ICP waves was observed between steroid and placebo-treated groups from the recordings of 103 of these patients who were treated in Leeds General Infirmary.
Therapy to Reduce Raised ICP
There was no difference in the number of the hypnotic or osmotic infusions administered for the control of mean ICP above 20 mm Hg between steroid and placebo groups. Examination of the relationship between outcome at 6 months and the use of infusions reveals a statistically significantly greater mortality in the steroid group receiving hypnotic infusions (0.05 > p > 0.02), although this difference does not reach significance if patients with preintubation GCS scores of 8 or more are excluded.
1CP and Outcome
When peak unstimulated mean ICP during the first 48 hours of intensive care is compared with the outcome at 6 months, an elevated ICP is associated with a poor outcome (Table 7) . When outcome in patients with ICP 
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elevated to more than 20 mm Hg is compared in the steroid and placebo groups, there is a statistically significantly poorer outcome in the steroid group (0.05 > p > 0.02); but when patients with preintubation GCS scores of 8 or more are excluded, this trend fails to reach statistical significance (Table 8) . However, if this relationship is examined for patients with peak ICP's of more than 30 mm Hg, a statistically significantly poorer outcome is seen in the steroid-treated patients, whether or not those with preintubation GCS scores of 8 or more are excluded ( Table 8 ). The outcome differences between the two groups at these ICP levels do not appear to be attributable to variations in age distribution or to the incidence of intracranial hematomas. It appears that steroid therapy in patients with elevated ICP is associated with a worse outcome.
Side Effects
One patient in the steroid-treated group and three in the placebo group had evidence of minor GI tract bleeding as evidenced by blood staining of the nasogastric aspirate, but no patient suffered GI bleeding severe enough to necessitate blood transfusion. Analysis of the hemoglobin concentration in 49 patients from the steroid group and 50 from the placebo group at 48 hours after admission to the ICU revealed no significant difference, and there was no significant difference in transfusion requirements between the two groups. The 48-hour ICU neutrophil count, platelet count, plasma sodium values, and potassium and urea concentrations in the above patients did not differ between the two groups.
The 48-hour plasma glucose concentrations in 56 patients from the steroid group and 48 patients from the placebo group were measured and showed a higher mean value in the steroid group (8.06 _+ 0.35 mmoles/ liter as compared to 6.57 _+ 0.22 mmoles/liter, mean __+ standard error of the mean, p < 0.001). In an effort to ascertain the effect of steroid therapy on the incidence of respiratory complications, the duration of ventilation and intensive care therapy was examined in the steroid-and placebo-treated groups. Both the period of ventilation and the duration of intensive care were shorter in the steroid group, but not significantly so. The duration of intensive care was also shorter in the steroid group after exclusion of patients dying in the ICU, but the difference was not statistically significant (Tables 9 and 10 ).
Discussion
The anti-inflammatory, immunosuppressive, and membrane-stabilizing properties of glucocorticoids might imply a favorable influence of steroid therapy in severe head injury. The effects of steroid therapy on vasogenic edema associated with cerebral tumors 9 and the suggestion that glucocorticoids might reduce cerebrospinal fluid (CSF) formation rate 27 would support such a hypothesis. Experimental work in head-injured animals has suggested that glucocorticoid administration, especially in high dosage, favorably influences lesion healing and recovery. The glucocorticoids methylprednisolone and, more recently, dexamethasone have been investigated clinically in head injury. Dexamethasone is probably the agent of choice because of its enhanced anti-inflammatory action consequent to 9-alpha-fluorine substitution, minimal mineral-corticoid activity (sodium retention, potassium excretion, and hypertension) because of a 16-alpha-methyl group, and slow metabolism (t,j, plasma 5 hours) attributable to a 1-2 double bond. Clinical trials of steroid therapy in head-injured patients vary widely in their conclusions. This may be due to deficiencies in study design, including one or more of the following: 1) absence of a standardized management regimen (and differences in management between studies); 2) differences in age range and distribution, severity of head injury, incidence of associated injuries, or pathological nature of head injury; 3) absence of a control group; 4) lack of blinding of the study; 5) comparison of treatments used at different time periods; 6) administration of different steroids at varying time intervals after injury, in different dosages by alternative routes, and for different durations (with or without phenytoin or other mono-oxygenase enzyme inducers); 7) failure to measure ICP; or 8) inadequate documentation of side effects. Several of the early clinical studies failed to demonstrate any benefit from low-dose steroid therapy after severe head injury. 1''2
The first study of high-dose methylprednisolone in the management of head injury was conducted by Sparacio, et al. 25 Their 36 patients each received a 40-mg intravenous bolus; then (intramuscularly) 40 mg/4 hrs for 7 days, 20 mg/4 hrs for 2 days, 20 mg/8 hrs for 2 days, and 20 mg/12 hrs for 2 days. Although the trial was uncontrolled, the mortality rate was considered excessive in the 24 patients with intracranial hematomas when compared to the authors' previous experience. However, outcome was considered superior in the remaining 12 patients with diffuse injury.
The first trial attempting to compare no steroid, and low-and high-dose steroid therapy in head injury was conducted by Gobiet, et al. l~ Each therapy group of patients came from a different year so that in Year 1 of the study none of the 35 patients received steroids, in the 2nd year 24 patients received low-dose dexamethasone (16 mg, then 16 mg/day for 8 days), and in the 3rd year 34 patients were treated with high-dose dexamethasone (48 mg, then 8 mg/2 hrs for 1 day, 4 mg/2 hrs on Day 2, 8 mg/2 hrs on Day 3, 4 mg/2 hrs on Day 4, and then 4 mg/4 hrs on Days 5 to 8). Any tendency for results to improve with experience would therefore have favored the high-dose steroid group. In all, 93 patients were studied and all underwent hyperventilation therapy with extradural ICP monitoring. It was claimed that high-dose dexamethasone therapy resulted in a significant reduction in mortality compared to patients in low-dose steroid groups. However, chisquare analysis of their figures with Yates correction fails to demonstrate statistical significance.
The first double-blind study to compare placebo, lowdose dexamethasone (10 mg intravenously, then 4 mg/ 6 hrs for 6 days), and high-dose dexamethasone (60 mg intravenously, then 24 mg/6 hrs for 6 days) in adult patients following severe closed head injury was that of Faupel, et al. 7 Outcome, based on disability on the day of discharge, was significantly improved in the pooled steroid group and in the two steroid groups separately. However, this conclusion was reached by comparing the number of deaths with the number of recoveries.
Mortality rate in the combined steroid groups was 24% compared to 57% in the control group.While this difference reaches statistical significance, it is noteworthy that 25.4 % of the pooled steroid groups were vegetative compared to 3.6% of the placebo group and 11.9% were severely disabled compared to 7.1% in the control group. Comparing the combined good, moderate disability, and severely disabled groups with combined vegetative survival and deaths reveals that there was no statistically significant difference between the control and the pooled steroid groups. Furthermore, chi-square analysis with Yates correction reveals no difference between the outcome of low-and high-dose steroid groups. In that study, patients receiving steroids less than 6 hours after their accident had a better outcome compared to the placebo group than did patients receiving therapy more than 6 hours after injury. However, the comparison is once again based on death or survival rather than good or bad outcome, and comparison of the pooled steroid groups treated before and after 6 hours of injury using chi-square analysis with Yates correction reveals no difference in outcome (death versus survival).
In the last 5 years, the results of three double-blind controlled trials of high-dose steroid therapy after severe head injury have been published. Cooper, et aL, 5 studied 76 comatose patients (Grady Coma Scale score 3, 4, or 5 on admission after resuscitation) managed by hyperventilation, ICP monitoring, and osmotherapy; 27 of these patients received 6 days of placebo, 25 received low-dose dexamethasone (16 mg/day), and 24 received high-dose dexamethasone (98 mg/day), the first dose of steroids being administered within 6 hours of injury. No significant benefit on the 6-month mortality or morbidity rates emerged from either dose of steroids. Good recovery occurred in 37% of patients receiving placebo, 44% of those receiving low-dose, and 29% of those treated with high-dose dexamethasone. Failure to detect an effect with high-dose steroids could have been due to the small sample size.
Cooper, et al., 5 also reported the postmortem findings in 32 of the 39 fatalities. It emerged that classification of patients into focal or diffuse injury based on admission clinical criteria was often an oversimplification of the postmortem findings. The authors estimated that 90% of the patients who died probably had an intracranial lesion which steroid therapy could not have influenced. The finding that patients classified as having focal lesions on admission often had concomitant diffuse disruption of the brain at postmortem examination also serves to emphasize the substantial difference in some animal models where focal lesions occur in isolation.
The second double-blind study was reported by Saul and coworkers. 24 That study was carried out in 100 comatose (GCS score of 7 or less) head-injured patients without associated injuries who were admitted over an 18-month period. Half of the patients received high-dose methylprednisolone (250 mg intravenously, then 125 mg/6 hrs intravenously) or dexamethasone in equipotent dosage; the remainder were controls. Patients were managed by hyperventilation, ICP monitoring, and treatment with osmotherapy and/or CSF drainage. After 3 days, patients were assessed and classified as either early responders (if their GCS score had improved to more than 8) or nonresponders. Outcome at 6 months based on the Glasgow Outcome Scale did not differ between the two groups when the death or vegetative survival group was compared with the disabled or good recovery group. However, a tendency for early responders in the steroid group to have a higher incidence of good recovery was observed, and a worse outcome was found in the nonresponders steroidtreated group. While these differences did not reach statistical significance, the authors suggested that different types of injury might respond differently to steroid therapy and therefore steroids should be given for 3 days to all patients and be continued thereafter only in early responders. It is noteworthy that this study with an overall mortality rate of only 17% consisted of a selected population of head injury in that only patients who survived 3 days were included. There was also a low incidence of surgical lesions and of associated injuries.
The most recent study was published by Braakman, et al., 2 and involved 161 patients with GCS scores of 8 or less on admission (but not including patients deemed dead on arrival at the hospital or patients improving to scores of more than 8). All patients received an intravenous bolus of 100 mg dexamethasone or placebo within 6 hours of injury, most within 3 hours. Intravenous steroid therapy was continued at 100 mg/day for 4 days, 16 mg/day on Days 5 to 7, and then 12, 8, and 4 rag/day over the next 3 days, respectively. Patients were managed by resuscitation, computerized tomography, surgery if appropriate, and in some cases ICP monitoring and controlled hyperventilation. The groups were well matched for severity of head injury and incidence of associated injuries.
Braakman, et al., 2 used a sequential statistical analysis of the 1-month outcome between pairs of patients from steroid and placebo groups. Using a null hypothesis, 2.5% boundary zones were drawn, one indicating that steroids significantly improve the rate of survival and the other that they significantly lower survival rate (95% probability). After the 161 patients had been studied it became clear from their results that the upper boundary zone was impossible to reach. No significant difference in the 6-month outcome was found between the two groups, although the number of deaths appeared higher in the placebo group while severe disability or vegetative survival predominated in the steroid group. By classifying patients according to their predicted outcome, based on clinical criteria on admission, the authors were unable to define any subgroup that was favorably influenced by steroid therapy.
In our view, only the last two studies reviewed contain a sufficient number of patients, including a control group, to provide evidence on the place of steroids in head injuries. Our results confirm the conclusions of Braakman, et al., 2 in that the 6-month outcome did not differ significantly between the steroid and placebo groups and no subgroup of the patient population significantly improved with steroid therapy.
In the current study, subdivision of patient groups according to intracranial pathology showed no benefit of steroid treatment in patients with no surgical lesion, contrary to the conclusions of Sparacio and colleagues. 25 However, the trend of a higher mortality rate in patients with surgically treatable lesions managed with steroids, reported by those authors, is supported in our data. This was despite a higher number of patients with a surgically treated lesion in the steroid group having a preintubation GCS score of 8 or more (13 patients in the steroid group, three in the placebo group), a factor that was not obviously explained by differences in age distribution or associated injury between steroid and placebo groups. Nevertheless, the comments of Cooper, et al., 5 regarding inaccuracies of premortem pathological classification should be remembered.
Previous studies have suggested a preponderance of vegetative survival in steroid-treated patients, 2"7 but this was not evident in our study.
As regards ICP, Miller and Leech 18 examined the effects of betamethasone therapy on ventricular fluid pressure and volume-pressure response (VPR) in seven neurosurgical patients, using each patient as his own control. No effect on ventricular fluid pressure was observed after 24 hours of steroid therapy, but a significant reduction in VPR suggestive of increasing cerebral compliance was recorded, It is to be noted that only one patient suffered head injury and the effect was most marked in the patient with meningioma. In the study by Gobiet, et al., ~~ the number of elevations of ICP was reported to be fewer in patients treated with high-dose steroids than those receiving low-dose or no steroids, and the requirement for mannitol was reduced in this group. Gudeman, et al., ~1 studied the effects of high-dose methylprednisolone on VPR and ICP in 20 consecutive severely head-injured patients, 12 of whom had mass lesions. Patients were used as their own controls, receiving steroids, 40 mg/6 hrs, until the start of the study, and then (intravenously) a 2-gin bolus, then 500 mg/6 hrs for 1 day, 250 mg/6 hrs for 1 day, and 40 mg/6 hrs to 72 hours. High-dose steroid therapy failed to influence ICP or VPR 24 and 48 hours after initiation.
Pitts and Katkis 22 failed to demonstrate any benefit on ICP response during 7 days of low-dose (16 mg/day) or high-dose (24 rag/day) dexamethasone therapy when compared to a control group. The ICP and results of osmotherapy were monitored in all 76 patients managed with hyperventilation, but only 36 of these received high-dose steroids. Similarly, Saul, et al., 24 reported no effect of steroid treatment on ICP in their study of 100 patients, of whom half received high-dose steroids.
This present study is the first to compare the ICP trend in all patients investigated. No difference in mean ICP, its course, or the incidence of fluctuations or waves between steroid or placebo groups or subgroups has emerged. There was no evidence that the number of patients requiring ICP control with hypnotic infusion or mannitol was reduced in the steroid group, or that the duration of such therapy was shorter in the steroid group, in contradiction to the results of Gobiet and coworkers.10 The well established relationship between ICP mortality was seen here again, but it is noteworthy that the 6-month outcome in patients with elevated ICP (> 20 mm Hg) was significantly worse in the steroid group. The influence of elevated ICP on the mortality rate applied even to patients with less severe injuries (preintubation GCS score of 8 or more). Eight patients from this group developed elevation of ICP over 20 mm Hg during the first 48 hours of intensive care therapy, with 50% mortality. In contrast, of the remaining 15 patients with preintubation GCS scores of 8 or more whose ICP remained below 20 mm Hg in this time period, only two patients (both over 60 years of age) died.
The incidence of side effects from steroid therapy was investigated by Marshall, et aL, I6 in 121 neurosurgical patients treated with three different dose regimens of dexamethasone: 36 patients received 16 mg/day, 43 patients 40 mg/day, and 42 patients 80 mg/day. No correlation between the dose of steroid and the risk of developing a complication was found. The low incidence of side effects led the authors to conclude that steroid therapy was safe in neurosurgical patients except in those with a preexisting history of GI hemorrhage or ulceration.
These conclusions are supported by Pitts and Katkis, 22 who found no significant difference in the complication rate between steroid-and placebo-treated groups, although hyperglycemia occurred in 20% of the steroid patients. On the other hand, Gudeman and coworkers 11 reported a higher complication rate: 85% of their 232 patients suffered hyperglycemia and 50% had GI bleeding severe enough to require blood transfusion. Gastrointestinal bleeding was not a major problem in the present study and the incidence did not differ significantly between the steroid and placebo groups. The low occurrence may reflect the relative insensitivity of the method of assessment, but no difference in transfusion requirements or 48-hour hemoglobin concentration emerged between the steroid and placebo groups. Our results therefore agree with those of Marshall, et aL, 16 Cooper, et al., 1~ and Braakman, et al. 2 The similarity of duration of assisted ventilation and intensive care (even after removal of patients who died in the ICU) between steroid and placebo groups suggests that the incidence of severe infection was not significantly different between the two groups and would support previous similar reports. 2,5A6 The present study resembles that of Braakman and coworkers 2 more closely than other studies in design and numbers of patients, and confirms their conclusion that high-dose dexamethasone is of no benefit following severe head injury. We conclude that, in the light of these two studies, the administration of glucocorticoids in the treatment of severe head injury is no longer indicated and, based on the observations of this study, may even be contraindicated in the presence of an elevated ICP.
